These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 33897898)
1. Repurposing Ruiz de Garibay G; García de Jalón E; Stigen E; Lund KB; Popa M; Davidson B; Safont MM; Rygh CB; Espedal H; Barrett TM; Haug BE; McCormack E Theranostics; 2021; 11(12):6044-6057. PubMed ID: 33897898 [TBL] [Abstract][Full Text] [Related]
2. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794 [TBL] [Abstract][Full Text] [Related]
3. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging. Vorobyeva AG; Stanton M; Godinat A; Lund KB; Karateev GG; Francis KP; Allen E; Gelovani JG; McCormack E; Tangney M; Dubikovskaya EA PLoS One; 2015; 10(6):e0131037. PubMed ID: 26110789 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560 [TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET. Bejot R; Kersemans V; Kelly C; Carroll L; King RC; Gouverneur V; Elizarov AM; Ball C; Zhang J; Miraghaie R; Kolb HC; Smart S; Hill S Nucl Med Biol; 2010 Jul; 37(5):565-75. PubMed ID: 20610161 [TBL] [Abstract][Full Text] [Related]
11. PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells. Güngör T; Önder FC; Tokay E; Gülhan ÜG; Hacıoğlu N; Tok TT; Çelik A; Köçkar F; Ay M Eur J Med Chem; 2019 Jun; 171():383-400. PubMed ID: 30928710 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614 [TBL] [Abstract][Full Text] [Related]
13. Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971 [TBL] [Abstract][Full Text] [Related]
14. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Lukashev AN; Fuerer C; Chen MJ; Searle P; Iggo R Hum Gene Ther; 2005 Dec; 16(12):1473-83. PubMed ID: 16390278 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049 [TBL] [Abstract][Full Text] [Related]
16. A mammalianized synthetic nitroreductase gene for high-level expression. Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451 [TBL] [Abstract][Full Text] [Related]
17. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy. Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330 [TBL] [Abstract][Full Text] [Related]
18. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. McCormack E; Silden E; West RM; Pavlin T; Micklem DR; Lorens JB; Haug BE; Cooper ME; Gjertsen BT Cancer Res; 2013 Feb; 73(4):1276-86. PubMed ID: 23233739 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy. Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235 [TBL] [Abstract][Full Text] [Related]
20. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]